Welcome to LookChem.com Sign In|Join Free

CAS

  • or
(3-bromo-5-fluorophenyl)methanamine, with the chemical formula C7H6BrFN, is a member of the amine family characterized by the presence of a bromine and fluorine atom attached to a benzene ring. This chemical compound serves as a versatile building block in pharmaceutical research and development, offering unique structural and functional properties that contribute to its potential applications in various fields.

1094555-68-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1094555-68-6 Structure
  • Basic information

    1. Product Name: (3-bromo-5-fluorophenyl)methanamine
    2. Synonyms: (3-bromo-5-fluorophenyl)methanamine;BENZENEMETHANAMINE, 3-BROMO-5-FLUORO-;3-Bromo-5-fluorobenzenemethanamine
    3. CAS NO:1094555-68-6
    4. Molecular Formula: C7H7BrFN
    5. Molecular Weight: 204.0395832
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1094555-68-6.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: 241℃
    3. Flash Point: 100℃
    4. Appearance: /
    5. Density: 1.571
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. PKA: 8.51±0.10(Predicted)
    10. CAS DataBase Reference: (3-bromo-5-fluorophenyl)methanamine(CAS DataBase Reference)
    11. NIST Chemistry Reference: (3-bromo-5-fluorophenyl)methanamine(1094555-68-6)
    12. EPA Substance Registry System: (3-bromo-5-fluorophenyl)methanamine(1094555-68-6)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1094555-68-6(Hazardous Substances Data)

1094555-68-6 Usage

Uses

Used in Pharmaceutical Research and Development:
(3-bromo-5-fluorophenyl)methanamine is utilized as a key building block for the synthesis of biologically active molecules, playing a crucial role in the discovery and development of new drugs. Its unique structure allows for the creation of diverse chemical entities with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (3-bromo-5-fluorophenyl)methanamine serves as a valuable component in the design and synthesis of novel compounds with potential therapeutic properties. Its presence in these molecules can modulate their pharmacological activity, selectivity, and pharmacokinetic profiles, contributing to the advancement of drug discovery efforts.
Used in Drug Discovery:
(3-bromo-5-fluorophenyl)methanamine is employed as a starting material in drug discovery processes, enabling the exploration of new chemical space and the identification of promising drug candidates. Its unique structural features can enhance the potency, selectivity, and safety of newly developed drugs, ultimately leading to more effective treatments for various diseases.
Used in Organic Synthesis:
As a reagent in organic synthesis, (3-bromo-5-fluorophenyl)methanamine is used for the preparation of complex organic compounds. Its versatile structure allows for the formation of a wide range of chemical products, making it an indispensable tool in the synthesis of advanced materials and specialty chemicals.
Used in the Development of New Drugs and Materials:
The unique structure and properties of (3-bromo-5-fluorophenyl)methanamine make it a valuable tool for the development of innovative drugs and materials. Its potential applications span across various industries, including pharmaceuticals, agrochemicals, and materials science, where it can contribute to the creation of novel products with improved performance and functionality.

Check Digit Verification of cas no

The CAS Registry Mumber 1094555-68-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,4,5,5 and 5 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1094555-68:
(9*1)+(8*0)+(7*9)+(6*4)+(5*5)+(4*5)+(3*5)+(2*6)+(1*8)=176
176 % 10 = 6
So 1094555-68-6 is a valid CAS Registry Number.

1094555-68-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name (3-bromo-5-fluorophenyl)methanamine

1.2 Other means of identification

Product number -
Other names (5-bromo-3-fluorophenyl)methylamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1094555-68-6 SDS

1094555-68-6Relevant articles and documents

STRAD-BINDING AGENTS AND USES THEREOF

-

Paragraph 1496-1498, (2021/08/06)

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0714; 0715, (2017/02/28)

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0667; 0668, (2017/02/28)

6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0672; 0673, (2017/02/28)

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

-

Paragraph 0686; 0687, (2017/02/28)

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0667; 0668, (2017/03/08)

7-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 7-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0704; 0705, (2017/02/28)

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

-

Paragraph 0686; 0687, (2017/03/08)

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0668, (2017/02/28)

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

-

Paragraph 0668, (2017/02/28)

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1094555-68-6